CONTACT US: Contact info
|
Citation |
Gupta AK. Osteopathic Family Physician 2012; 4(5): 149-154. |
|
Copyright |
(Copyright © 2012) |
|
DOI |
|
PMID |
unavailable |
|
Abstract |
Increasing overweight and obesity are major risk factors for the development of type 2 diabetes. The risk is higher when the weight gain occurs during adulthood. In fact, evidence shows that body mass index (BMI) is directly and continuously related to the risk of type 2 diabetes. Individuals with upper body obesity are at high risk for hyperinsulinemia, insulin resistance, and type 2 diabetes. According to the US Centers for Disease Control and Prevention, rates of type 2 diabetes have tripled in the past 30 years. This is caused largely by the rapid rise in the rate of obesity, a major risk factor for developing type 2 diabetes and pre-diabetes. Over the last decade, there has been a rapid escalation in the prevalence of obesity, one that parallels the equally rapid increase in type 2 diabetes. The development of type 2 diabetes can be delayed or sometimes prevented in individuals with obesity who are able to lose weight. In type 2 diabetes, weight loss improves glycemic control and cardiovascular disease risk factors. Strategies to decrease the risk of type 2 diabetes include behavior therapies in combination with healthy lifestyle changes, optimizing medication for weight neutral effect, anti-obesity medication, and weight loss surgeries. © 2012 Elsevier Inc. Language: en |
|
Keywords |
human; suicide; depression; diet; risk assessment; Obesity; review; obesity; mental disease; weight reduction; unclassified drug; priority journal; drug safety; food and drug administration; seizure; drug efficacy; nausea; weight gain; drug withdrawal; patient counseling; non insulin dependent diabetes mellitus; sulfonylurea; metformin; monotherapy; dizziness; body mass; insulin resistance; hyperinsulinemia; impaired glucose tolerance; tetrahydrolipstatin; adrenergic receptor stimulating agent; bariatric surgery; caloric restriction; lifestyle modification; weight control; exendin 4; pramlintide; rimonabant; antiobesity agent; glycemic control; Weight management; amfebutamone plus naltrexone; lorcaserin; phentermine plus topiramate; adipocyte; liraglutide; locaserine; Pharmacology of obesity; Pre-diabetes; Type II diabetes; very low calorie diet |